|
1
|
Uemura H, Hoshino K and Kubota Y:
Engagement of renin-angiotensin system in prostate cancer. Curr
Cancer Drug Targets. 11:442–450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
O'Mahony OA, Barker S, Puddefoot JR and
Vinson GP: synthesis and secretion of angiotensin II by the
prostate gland in vitro. Endocrinology. 146:392–398. 2005.
View Article : Google Scholar
|
|
3
|
Fujita M, Hayashi I, Yamashina S, Itoman M
and Majima M: Blockade of angiotensin AT1a receptor signaling
reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys
Res Commun. 294:441–447. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Namsolleck P, Recarti C, Foulquier S,
Steckelings UM and Unger T: AT(2) receptor and tissue injury:
Therapeutic implications. Curr Hypertens Rep. 16:4162014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haendeler J and Berk BC: Angiotensin II
mediated signal transduction. Important role of tyrosine kinases.
Regul Pept. 95:1–7. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McCarty MF: Targeting multiple signaling
pathways as a strategy for managing prostate cancer: Multifocal
signal modulation therapy. Integr Cancer Ther. 3:349–380. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rodrigues-Ferreira S and Nahmias C:
G-protein coupled receptors of the renin-angiotensin system: New
targets against breast cancer? Front Pharmacol. 6:242015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Uemura H, Hasumi H, Ishiguro H, Teranishi
J, Miyoshi Y and Kubota Y: Renin-angiotensin system is an important
factor in hormone refractory prostate cancer. Prostate. 66:822–830.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Moon JY: Recent update of
renin-angiotensin-aldosterone system in the pathogenesis of
hypertension. Electrolyte Blood Press. 11:41–45. 2013. View Article : Google Scholar
|
|
10
|
Santos RA, Ferreira AJ, Verano-Braga T and
Bader M: Angiotensin-converting enzyme 2, angiotensin-(1-7) and
Mas: New players of the renin-angiotensin system. J Endocrinol.
216:R1–R17. 2013. View Article : Google Scholar
|
|
11
|
Krishnan B, Torti FM, Gallagher PE and
Tallant EA: Angiotensin-(1-7) reduces proliferation and
angiogenesis of human prostate cancer xenografts with a decrease in
angiogenic factors and an increase in sFlt-1. Prostate. 73:60–70.
2013. View Article : Google Scholar
|
|
12
|
Krishnan B, Smith TL, Dubey P, Zapadka ME,
Torti FM, Willingham MC, Tallant EA and Gallagher PE:
Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces
osteoclastogenesis. Prostate. 73:71–82. 2013. View Article : Google Scholar
|
|
13
|
Hsing AW, Tsao L and Devesa SS:
International trends and patterns of prostate cancer incidence and
mortality. Int J Cancer. 85:60–67. 2000. View Article : Google Scholar
|
|
14
|
Stone KR, Mickey DD, Wunderli H, Mickey GH
and Paulson DF: Isolation of a human prostate carcinoma cell line
(DU 145). Int J Cancer. 21:274–281. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun YH, Gao X, Tang YJ, Xu CL and Wang LH:
Androgens induce increases in intracellular calcium via a G
protein-coupled receptor in LNCaP prostate cancer cells. J Androl.
27:671–678. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Falkenstein E, Tillmann HC, Christ M,
Feuring M and Wehling M: Multiple actions of steroid hormones - a
focus on rapid, nongenomic effects. Pharmacol Rev. 52:513–556.
2000.PubMed/NCBI
|
|
17
|
Guo Z, Benten WP, Krücken J and Wunderlich
F: Nongenomic testosterone calcium signaling. Genotropic actions in
androgen receptor-free macrophages. J Biol Chem. 277:29600–29607.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yeh CR, Da J, Song W, Fazili A and Yeh S:
Estrogen receptors in prostate development and cancer. Am J Clin
Exp Urol. 2:161–168. 2014.PubMed/NCBI
|
|
19
|
Vlahovic G and Crawford J: Activation of
tyrosine kinases in cancer. Oncologist. 8:531–538. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hirano AA, Greengard P and Huganir RL:
Protein tyrosine kinase activity and its endogenous substrates in
rat brain: A subcellular and regional survey. J Neurochem.
50:1447–1455. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Domińska K, Piastowska-Ciesielska AW,
Lachowicz-Ochędalska A and Ochędalski T: similarities and
differences between effects of angiotensin III and angiotensin II
on human prostate cancer cell migration and proliferation.
Peptides. 37:200–206. 2012. View Article : Google Scholar
|
|
22
|
Rebas E, Zabczyńska J and Lachowicz A: The
effect of angiotensin 1–7 on tyrosine kinases activity in rat
anterior pituitary. Biochem Biophys Res Commun. 347:581–585. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alimirah F, Chen J, Basrawala Z, Xin H and
Choubey D: DU-145 and PC-3 human prostate cancer cell lines express
androgen receptor: Implications for the androgen receptor functions
and regulation. FEBS Lett. 580:2294–2300. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Liu L, Hou J, Wen D, Yan C, Pu J,
Ouyang J and Pan H: Rapid membrane effect of testosterone in LNCaP
cells. Urol Int. 81:353–359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McPherson SJ, Ellem SJ and Risbridger GP:
Estrogen-regulated development and differentiation of the prostate.
Differentiation. 76:660–670. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Negri-Cesi P, Colciago A, Poletti A and
Motta M: 5α-reductase isozymes and aromatase are differentially
expressed and active in the androgen-independent human prostate
cancer cell lines DU145 and PC3. Prostate. 41:224–232. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Piccolella M, Crippa V, Messi E, Tetel MJ
and Poletti A: Modulators of estrogen receptor inhibit
proliferation and migration of prostate cancer cells. Pharmacol
Res. 79:13–20. 2014. View Article : Google Scholar
|
|
28
|
Bonkhoff H and Berges R: The evolving role
of oestrogens and their receptors in the development and
progression of prostate cancer. Eur Urol. 55:533–542. 2009.
View Article : Google Scholar
|
|
29
|
Ho SM: Estrogens and anti-estrogens: Key
mediators of prostate carcinogenesis and new therapeutic
candidates. J Cell Biochem. 91:491–503. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hoshino K, Ishiguro H, Teranishi J,
Yoshida S, Umemura S, Kubota Y and Uemura H: Regulation of androgen
receptor expression through angiotensin II type 1 receptor in
prostate cancer cells. Prostate. 71:964–975. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baiardi G, Macova M, Armando I, Ando H,
Tyurmin D and Saavedra JM: Estrogen upregulates renal angiotensin
II AT1 and AT2 receptors in the rat. Regul Pept. 124:7–17. 2005.
View Article : Google Scholar
|
|
32
|
Hilliard LM, Sampson AK, Brown RD and
Denton KM: The 'his and hers' of the renin-angiotensin system. Curr
Hypertens Rep. 15:71–79. 2013. View Article : Google Scholar
|
|
33
|
Marchiani S, Tamburrino L, Nesi G,
Paglierani M, Gelmini S, Orlando C, Maggi M, Forti G and Baldi E:
Androgen-responsive and -unresponsive prostate cancer cell lines
respond differently to stimuli inducing neuroendocrine
differentiation. Int J Androl. 33:784–793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Uemura H, Ishiguro H, Nakaigawa N,
Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A and Kubota Y:
Angiotensin II receptor blocker shows antiproliferative activity in
prostate cancer cells: A possibility of tyrosine kinase inhibitor
of growth factor. Mol Cancer Ther. 2:1139–1147. 2003.PubMed/NCBI
|
|
35
|
Ager EI, Neo J and Christophi C: The
renin-angiotensin system and malignancy. Carcinogenesis.
29:1675–1684. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ullén A, Farnebo M, Thyrell L, Mahmoudi S,
Kharaziha P, Lennartsson L, Grandér D, Panaretakis T and Nilsson S:
Sorafenib induces apoptosis and autophagy in prostate cancer cells
in vitro. Int J Oncol. 37:15–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Brooks C, Sheu T, Bridges K, Mason K,
Kuban D, Mathew P and Meyn R: Preclinical evaluation of sunitinib,
a multi-tyrosine kinase inhibitor, as a radiosensitizer for human
prostate cancer. Radiat Oncol. 7:154–163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ławnicka H, Potocka AM, Juzala A,
Fournie-Zaluski MC and Pawlikowski M: Angiotensin II and its
fragments (angiotensins III and IV) decrease the growth of DU-145
prostate cancer in vitro. Med Sci Monit. 10:BR410–bR413.
2004.PubMed/NCBI
|
|
39
|
Domińska K, Piastowska-Ciesielska AW,
Płuciennik E, Lachowicz-Ochędalska A and Ochedalski T: A comparison
of the effects of Angiotensin IV on androgen-dependent and
androgen-independent prostate cancer cell lines. J Renin
Angiotensin Aldosterone Syst. 14:74–81. 2013. View Article : Google Scholar
|
|
40
|
Brand TM, Iida M, Li C and Wheeler DL: The
nuclear epidermal growth factor receptor signaling network and its
role in cancer. Discov Med. 12:419–432. 2011.PubMed/NCBI
|
|
41
|
Montero JC, Seoane S, Ocaña A and
Pandiella A: Inhibition of SRC family kinases and receptor tyrosine
kinases by dasatinib: Possible combinations in solid tumors. Clin
Cancer Res. 17:5546–5552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rebas E and Lachowicz-Ochedalska A: The
effect of angiotensin III on protein tyrosine kinase activity in
rat pituitary. Regul Pept. 130:14–18. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lewandowska U, Lachowicz-Ochędalska A,
Domińska K, Kaszewska D and Rębas E: Angiotensin II as a factor
modulating protein tyrosine kinase activity in two breast cancer
lines -MCF-7 and MDA-MB-231. Endokrynol Pol. 62:151–158. 2011.
|
|
44
|
Reis AB, Araújo FC, Pereira VM, Dos Reis
AM, Santos RA and Reis FM: Angiotensin (1–7) and its receptor Mas
are expressed in the human testis: Implications for male
infertility. J Mol Histol. 41:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Uemura H, Nakaigawa N, Ishiguro H and
Kubota Y: Antiproliferative efficacy of angiotensin II receptor
blockers in prostate cancer. Curr Cancer Drug Targets. 5:307–323.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chow L, Rezmann L, Catt KJ, Louis WJ,
Frauman AG, Nahmias C and Louis SNS: Role of the renin-angiotensin
system in prostate cancer. Mol Cell Endocrinol. 302:219–229. 2009.
View Article : Google Scholar
|
|
47
|
Pawlikowski M, Minias R, Sosnowski M and
Zieliński KW: Immu no histochemical detection of angiotensin AT 1
and AT 2 receptors in prostate cancer. Cent European J Urol.
64:252–255. 2011. View Article : Google Scholar
|
|
48
|
Waters C, Pyne S and Pyne NJ: The role of
G-protein coupled receptors and associated proteins in receptor
tyrosine kinase signal transduction. Semin Cell Dev Biol.
15:309–323. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chow L, Rezmann L, Imamura K, Wang L, Catt
K, Tikellis C, Louis WJ, Frauman AG and Louis SN: Functional
angiotensin II type 2 receptors inhibit growth factor signaling in
LNCaP and PC3 prostate cancer cell lines. Prostate. 68:651–660.
2008. View Article : Google Scholar : PubMed/NCBI
|
